Market Closed -
Nasdaq
21:00:00 28/06/2024 BST
5-day change
1st Jan Change
0.89
USD
-2.20%
-4.22%
+21.09%
Presentation Operator MessageOperator (Operator)Welcome to the AcelRx's Fourth Quarter and Ful...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Talphera, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-14
CI
Transcript : Talphera, Inc., Q1 2024 Earnings Call, May 14, 2024
05-14
Talphera, Inc. Appoints Dr. Shakil Aslam as Chief Development Officer, Effective May 20, 2024
05-14
CI
Talphera, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
03-06
CI
Transcript : Talphera, Inc., Q4 2023 Earnings Call, Mar 06, 2024
03-06
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
03-06
CI
Talphera, Inc. Announces Management Changes
03-01
CI
Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director
01-22
CI
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million
01-18
MT
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.
01-17
CI
Talphera, Inc. announced that it expects to receive $16 million in funding from Nantahala Capital Management, LLC, Rosalind Advisors, Inc.
01-16
CI
AcelRx Pharmaceuticals, Inc. will Change its Ticker to TLPH from ACRX
01-10
CI
Talphera Expects to Initiate the Registrational Study of Niyad
01-09
CI
Talphera, Inc.(NasdaqGM:TLPH) dropped from NASDAQ Composite Index
01-09
CI
AcelRx Pharmaceuticals, Inc. has Changed its Name to Talphera, Inc
01-09
CI
Transcript : AcelRx Pharmaceuticals, Inc. - Special Call
12-06
Transcript : AcelRx Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
11-08
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023
11-08
CI
AcelRx Pharmaceuticals, Inc. Receives IDE Approval for Niyad and Advances to A Single Registration Study
03/10/23
CI
Alliance Global Initiates AcelRx Pharmaceuticals at Buy With $4.25 Price Target
02/10/23
MT
HC Wainwright Adjusts AcelRx Pharmaceuticals Price Target to $5 From $8, Maintains Buy Rating
25/09/23
MT
North American Morning Briefing : Focus Shifts to -2-
21/08/23
DJ
HC Wainwright Upgrades AcelRx Pharmaceuticals to Buy From Neutral, Price Target is $8
18/08/23
MT
Transcript : AcelRx Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023
10/08/23
AcelRx Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
10/08/23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Companyâs nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.
More about the company
Last Close Price
0.89
USD
Average target price
4.417
USD
Spread / Average Target
+396.26%
Consensus
1st Jan change
Capi.
+21.09% 15.12M +7.39% 72.09B +15.93% 9.05B -22.81% 4.4B +17.59% 4.39B +25.93% 3.94B +4.64% 2.1B +9.09% 1.97B -36.86% 1.87B -0.50% 1.64B
Specialty & Advanced Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1